# Clinical Trial to Evaluate the Safety and Efficacy of SCAI-001 Compared to Restasis

> **NCT05733624** · PHASE2 · COMPLETED · sponsor: **SCAI Therapeutics** · enrollment: 116 (actual)

## Conditions studied

- Dry Eye Syndromes

## Interventions

- **DRUG:** SCAI-001 0.01% eyedrop
- **DRUG:** SCAI-001 0.02% eyedrop
- **DRUG:** Restasis 0.05% eyedrop

## Key facts

- **NCT ID:** NCT05733624
- **Lead sponsor:** SCAI Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-01-05
- **Primary completion:** 2023-08-23
- **Final completion:** 2024-02-02
- **Target enrollment:** 116 (ACTUAL)
- **Last updated:** 2024-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05733624

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05733624, "Clinical Trial to Evaluate the Safety and Efficacy of SCAI-001 Compared to Restasis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05733624. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*